MA48048A - Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate - Google Patents

Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate

Info

Publication number
MA48048A
MA48048A MA048048A MA48048A MA48048A MA 48048 A MA48048 A MA 48048A MA 048048 A MA048048 A MA 048048A MA 48048 A MA48048 A MA 48048A MA 48048 A MA48048 A MA 48048A
Authority
MA
Morocco
Prior art keywords
glutamate receptor
metabotropic glutamate
allosteric modulator
chromone oxime
new chromone
Prior art date
Application number
MA048048A
Other languages
English (en)
French (fr)
Inventor
Delphine Charvin
Francois Conquet
Baptiste Manteau
Vincent Pomel
Original Assignee
Prexton Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prexton Therapeutics Sa filed Critical Prexton Therapeutics Sa
Publication of MA48048A publication Critical patent/MA48048A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA048048A 2014-08-27 2015-08-27 Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate MA48048A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14182468 2014-08-27

Publications (1)

Publication Number Publication Date
MA48048A true MA48048A (fr) 2020-02-12

Family

ID=51421865

Family Applications (3)

Application Number Title Priority Date Filing Date
MA048048A MA48048A (fr) 2014-08-27 2015-08-27 Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate
MA040530A MA40530A (fr) 2014-08-27 2015-08-27 Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate
MA052702A MA52702A (fr) 2014-08-27 2015-08-27 Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA040530A MA40530A (fr) 2014-08-27 2015-08-27 Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate
MA052702A MA52702A (fr) 2014-08-27 2015-08-27 Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate

Country Status (26)

Country Link
US (3) US10017521B2 (OSRAM)
EP (3) EP3186257B1 (OSRAM)
JP (1) JP6430015B2 (OSRAM)
KR (1) KR101870589B1 (OSRAM)
CN (2) CN106715444B (OSRAM)
AU (1) AU2015308438B2 (OSRAM)
CA (1) CA2956191C (OSRAM)
CY (1) CY1121352T1 (OSRAM)
DK (1) DK3186257T3 (OSRAM)
ES (1) ES2714073T3 (OSRAM)
HR (1) HRP20190343T1 (OSRAM)
HU (1) HUE041941T2 (OSRAM)
IL (1) IL250287B (OSRAM)
LT (1) LT3186257T (OSRAM)
MA (3) MA48048A (OSRAM)
ME (1) ME03339B (OSRAM)
MX (1) MX369643B (OSRAM)
NZ (1) NZ728853A (OSRAM)
PL (1) PL3186257T3 (OSRAM)
PT (1) PT3186257T (OSRAM)
RS (1) RS58592B1 (OSRAM)
RU (1) RU2672569C2 (OSRAM)
SI (1) SI3186257T1 (OSRAM)
SM (1) SMT201900152T1 (OSRAM)
TR (1) TR201903332T4 (OSRAM)
WO (1) WO2016030444A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3186257B1 (en) * 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HRP20192250T1 (hr) 2015-08-27 2020-05-15 Prexton Therapeutics Sa Derivat kromon oksima koji prodire u mozak za liječenje diskinezije uzrokovane levodopom
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
US20070027216A1 (en) 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
SG10201401661RA (en) 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
US20140349994A1 (en) * 2012-01-18 2014-11-27 Addex Pharma S.A. Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
EP3186257B1 (en) * 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HRP20192250T1 (hr) 2015-08-27 2020-05-15 Prexton Therapeutics Sa Derivat kromon oksima koji prodire u mozak za liječenje diskinezije uzrokovane levodopom

Also Published As

Publication number Publication date
CN106715444B (zh) 2019-07-12
CN106715444A (zh) 2017-05-24
KR20170042624A (ko) 2017-04-19
RU2017109818A (ru) 2018-10-01
KR101870589B1 (ko) 2018-06-25
EP3186257A1 (en) 2017-07-05
CA2956191C (en) 2020-01-28
PT3186257T (pt) 2019-03-27
US10442818B2 (en) 2019-10-15
HRP20190343T1 (hr) 2019-05-31
IL250287B (en) 2020-02-27
WO2016030444A1 (en) 2016-03-03
CN110343118A (zh) 2019-10-18
LT3186257T (lt) 2019-04-25
JP6430015B2 (ja) 2018-11-28
EP3696183A1 (en) 2020-08-19
AU2015308438B2 (en) 2018-12-13
CA2956191A1 (en) 2016-03-03
TR201903332T4 (tr) 2019-03-21
EP3186257B1 (en) 2019-02-06
RS58592B1 (sr) 2019-05-31
EP3502115A1 (en) 2019-06-26
JP2017525776A (ja) 2017-09-07
ES2714073T3 (es) 2019-05-27
DK3186257T3 (en) 2019-04-01
US20170253613A1 (en) 2017-09-07
NZ728853A (en) 2018-04-27
MX2017002429A (es) 2017-08-02
IL250287A0 (en) 2017-03-30
CY1121352T1 (el) 2020-05-29
MX369643B (es) 2019-11-15
SMT201900152T1 (it) 2019-05-10
AU2015308438A1 (en) 2017-03-02
US10017521B2 (en) 2018-07-10
RU2017109818A3 (OSRAM) 2018-10-01
MA40530A (fr) 2017-07-05
ME03339B (me) 2019-10-20
HUE041941T2 (hu) 2019-06-28
SI3186257T1 (sl) 2019-07-31
RU2672569C2 (ru) 2018-11-16
MA52702A (fr) 2021-03-31
US20200024285A1 (en) 2020-01-23
US20180291034A1 (en) 2018-10-11
PL3186257T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
HUE057254T2 (hu) Vegyületek és készítmények az endoszomális Toll-szerû receptorok inhibitoraiként
PT3160964T (pt) Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos
LT3322701T (lt) Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3200806A4 (en) Nanofiber structures and methods of synthesis and use thereof
HUE045161T2 (hu) Hozzáadott emulgeálószerektõl, pufferektõl és stabilizáló sóktól mentes krémpor
HRP20190147T1 (hr) Benzoksazinon amidi kao modulatori mineralokortikodnih receptora
DK3137873T3 (da) Viscometer and methods of use thereof
DK3707143T3 (da) Nye analoger som androgenreceptor- og glucorticoidreceptor-modulatorer
EP3367998A4 (en) NOVEL METHOD OF USE AND COMPOSITIONS
IL248792A0 (en) Hsp70 modulators and methods for making and using the same
EP3368401A4 (en) ANCHOR ADAPTER
EP3191117A4 (en) Stimulation of ovarian follicle development and oocyte maturation
PL2989875T3 (pl) Mechanizm dźwigni narzędzia rolniczego
EP3171941A4 (en) N-methyl-d-aspartate receptor modulators and methods of making and using same
MA52702A (fr) Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate
IL251230A0 (en) Converted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
PL3431106T3 (pl) Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
BR112017007799A2 (pt) dispositivo intrauterino com um movimento restrito de um nó da corda
HUE050459T2 (hu) Androgénreceptor-gátló kristályformája és annak elõállítási eljárása
EP3659592A4 (en) Novel benzylideneacetone derivative and use thereof
HUE053734T2 (hu) 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
EP3463342A4 (en) COMBINATIONS OF ESTROGEN RECEPTOR MODULATORS
EP3161483A4 (en) Point of care immunization testing system - detection methods
UA36533S (uk) Бланк документу про вищу освіту тернопільського національного технічного університету імені івана пулюя